prostate cancer, and compared it to a base model consisting of age, digital rectal exam findings, and PSA. Additionally, we compared the performance of the 4Kscore test in AA and non-AA men.
INTRODUCTION AND OBJECTIVES: There are currently no validated DNA based biomarkers available for routine clinical use to predict prostate cancer recurrence after prostatectomy. The Genomic Evaluators of Metastatic Cancer of the Prostate (GEMCaP) assay was developed to predict recurrence using a tumor genotype derived from copy number for a set of genomic loci. We aim to validate the GEMCaP assay using a separate cohort from the development cohort.
METHODS: We randomly selected 203 patients who had undergone radical prostatectomy at the Cleveland Clinic (CC) or the University of Rochester (UR) Cancer Centers from 2000-2005 and had tumor tissue available for research. After pathology review cancer tissues were macrodissected and DNA was extracted and subjected to high resolution array comparative genomic hybridization (aCGH). A high GEMCaP score was defined as >20% of the genomic loci exhibiting copy number gain or loss in a given tumor, as in previous studies.
Cox regression was used to evaluate associations between the GEM-CaP score and risk of biochemical recurrence. RESULTS: We report the results from 140 patients, 54 from the CC cohort and 86 from the UR cohort. Overall, 38% of patients recurred with a median time to recurrence of 45 months. Based on the CAPRA-S score, 39% were low-risk, 42% were intermediate-risk and 19% were high-risk. Thirty-one percent of the cohort had a high GEMCaP score (¼20%). A high GEMCaP score was associated with higher risk of biochemical recurrence (HR 2.69, 95% CI 1.51-4.77) and remained associated with biochemical recurrence after adjusting for the CAPRA-S score (HR 1.91, 95% CI 1.05-3.48). The C-index for GEMCaP alone was 0.64, and improved when combined with CAPRA-S (C-index ¼ 0.76).
CONCLUSIONS: In this validation study, a high GEMCaP score was associated with biochemical recurrence in two external cohorts. This remained true after adjusting for clinical and pathologic factors as accounted for by the CAPRA-S score. The GEMCaP biomarker could be an efficient and effective clinical risk assessment tool to identify prostate cancer patients for early adjuvant therapy.
Source of Funding: NIH
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CTC-BASED GENE EXPRESSION FOR PREDICTING RESISTANCE TO ABIRATERONE AND ENZALUTAMIDE IN MCRPC
Jae-Seung Chung*, Yugang Wang, Henderson James, Udit Singhal, Yuanyuan Qiao, Alexander Zaslavsky, Dan Hovelson, Ann Arbor, MI; Felix Feng, San Francisco, CA; Ganesch Palapattu, Taichman Russell, Arul Chinnaiyan, Scott Tomlins, Todd Morgan, Ann Arbor, MI INTRODUCTION AND OBJECTIVES: There is a continued need to develop liquid biomarkers that predict response to 2nd generation hormonal therapies. While circulating tumor cell (CTC)-based detection of AR-V7 has been shown to be one potential marker, the apparent rarity of AR-V7 positivity is indicative of the importance of other drivers of resistance in this setting. We sought to utilize a multiplex gene expression platform for assessing CTCs in order to determine other potential predictive biomarkers of response to abiraterone and enzalutamide.
METHODS: Whole blood (~5mL) was obtained from 37 patients with metastatic castration resistant prostate cancer (mCRPC) starting enzalutamide (n¼16) or abiraterone (n¼21). CTCs were isolated using anti-EpCAM-conjugated magnetic beads, and following cell lysis, mRNA was extracted followed by multiplex qRT-PCR for 44 prostate cancer-related genes plus internal controls. Gene expression was normalized to controls, and samples were considered CTC-positive based on a previously established set of epithelial markers (EpCAM, EGFR, DSG2, KRT8, KRT18 and KRT19). The primary endpoint was PSA progression-free survival (PFS), with PSA progression defined as an increase of 25% or more above the nadir. Univariable Cox regression analyses were performed to assess for genes associated with PFS at false discovery rate (FDR) < 0.20. RESULTS: We identified 27 (73%) patients with detectable CTCs among the 37mCRPC patients. The median age of the cohort was 73 years (IQR 64-78), and patients were followed for a median of 7.4 months (IQR 3.8-18.5). A total of 22 (81.5%) patients suffered PSA progression at a median time of 3.3 months (IQR 1.5-6.8). In the Cox analysis, PSMA (HR 3.83, 95%CI 1.62-9.03, p¼0.002), TSPAN8 (HR 2.04, 95%CI 1.21-3.46, p¼0.008), BMP7 (HR 1.46, 95%CI 1.09-1.95, p¼0.017), and GAS6 (HR 2.29, 95%CI 1.16-4.51, p¼0.017) were independent predictors of shorter PFS.
CONCLUSIONS: We identified four prostate cancer-related genes that can be identified in CTCs and appear to predict short PFS in men with mCRPC being treated with enzalutamide or abiraterone. While this is a small cohort and prospective validation is needed, these findings highlight the potential role for this approach in helping guide therapy choice.
